Research on Toxoplasmosis reveals potential vaccine strategy targeting essential splicing protein, offering protection ...

A South Korean biotech company is likely to benefit greatly from the policy of the U.S. Food and Drug Administration, which ...

Digihub Technology Solutions, Benin City, in partnership with Quadorra Technology, has launched a hackathon to provide a ...

The Mohammed VI Polytechnic University (UM6P) in Benguerir wrapped up the second edition of the Deep Tech Summit (DTS) this ...

ALT5 Sigma will exhibit at Booth #2023 and is proud to be a sponsor of Opening Night, one of the premier events kicking off the week. Consensus 2025 is the most influential gathering for the crypto, ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Gene therapy marks India's first major leap in treating hemophilia * Biotechnology sector grows to over 165 billion dollars, ...

Gyre Therapeutics ("Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 ...

Surrozen, Inc. ('Surrozen” or the 'Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with ...

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

Portsmouth experts will lead an exciting event exploring innovative technologies in healthcare and environmental science ...

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate init ...